PTGS2 and breast cancer: It is worth mentioning that SFN can time and dose-dependently activate NF-κB nuclear translocation in T24 BC cells and inhibit NF-κB DNA binding to the COX-2 promoter, thereby inhibiting COX-2 mRNA and protein levels (Shan et al., 2009) (Figure 8).